Prosecution Insights
Prosecution Insights
Tech Center 3700 • Art Units: 1600 1632 1636 3774
This examiner grants 43% of resolved cases
Anoop Kumar Singh serves in Art Unit 1600 under Tech Center 3700. Across 721 resolved cases, the examiner has an allowance rate of 43.0%. This suggests a challenging environment for applicants. The interview lift of 67.6% is exceptionally high, indicating that interviews are a vital tool for overcoming examiner objections. The median days to allowance is 1541.
Given the 43.0% allowance rate, practitioners should strongly consider interviews to navigate the 1541-day pendency. The 67.6% interview lift is one of the most significant metrics for Art Unit 1600. Across 721 resolved cases, the examiner has demonstrated that verbal advocacy is highly effective in Tech Center 3700. Strategy should prioritize direct engagement to improve the 43.0% baseline grant probability. The 1541-day median timeline should be factored into all planning.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17912690 | GENE THERAPY FOR COCKAYNE SYNDROME | Final Rejection | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. |
| 18649612 | CELL DISSOCIATION SOLUTION, CELL DISSOCIATION METHOD, AND CELL PRESERVATION METHOD | Non-Final OA | CANON KABUSHIKI KAISHA |
| 16428138 | Methods and Compositions for Treating Dystroglycanopathy Disorders | Final Rejection | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL |
| 18510060 | Methods of Treating Cancer and Infectious Diseases Using Cell Based Therapies | Non-Final OA | Emory University |
| 17259766 | COMPOSITIONS AND METHODS FOR REPROGRAMMING SKIN INTO INSULIN PRODUCING TISSUE | Non-Final OA | Ohio State Innovation Foundation |
| 18949619 | CELLS LACKING B2M SURFACE EXPRESSION AND METHODS FOR ALLOGENEIC ADMINISTRATION OF SUCH CELLS | Non-Final OA | President and Fellows of Harvard College |
| 18164502 | CELLS AND METHODS OF USES AND MAKING THE SAME | Non-Final OA | Washington University |
| 18698929 | ENGINEERED CARDIAC MUSCLE COMPOSITIONS | Non-Final OA | Massachusetts Institute of Technology |
| 19298798 | ADENO-ASSOCIATED VIRUS VECTOR DELIVERY OF MICRO-DYSTROPHIN TO TREAT MUSCULAR DYSTROPHY | Final Rejection | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL |
| 17626903 | Genetically Modified Non-Human Animals and Methods of Use Thereof | Non-Final OA | YALE UNIVERSITY |
| 18702258 | COMPOSITIONS USEFUL IN TREATMENT OF CDKL5 DEFICIENCY DISORDER (CDD) | Non-Final OA | The Trustees of the University of Pennsylvania |
| 17798796 | GENE THERAPY | Non-Final OA | UCL BUSINESS LTD |
| 17640422 | METHODS OF RESTORING LYSOSOMAL FUNCTION OF RETINAL PIGMENT EPITHELIAL CELLS BY ACTIVATION OF TFEB | Final Rejection | University of Pittsburgh - Of the Commonwealth System of Higher Education |
| 17924578 | COMPOSITIONS AND METHODS FOR PROMOTING HAIR CELL REGENERATION | Final Rejection | Decibel Therapeutics, Inc. |
| 16240472 | ADENO-ASSOCIATED VIRUS MEDIATED DELIVERY OF C1EI AS A THERAPY FOR ANGIOEDEMA | Final Rejection | Cornell University |
| 17775780 | ENHANCER POLYNUCLEOTIDE RESPONDING TO HEART FAILURE AND EXPRESSION VECTOR INCLUDING SAID ENHANCER POLYNUCLEOTIDE | Final Rejection | OSAKA UNIVERSITY |
| 17095216 | METHODS FOR IDENTIFYING ANTIGEN-SPECIFIC T CELL RECEPTORS | Non-Final OA | MEMORIAL SLOAN-KETTERING CANCER CENTER |
| 17584547 | CHIMERIC ANTIGEN RECEPTORS WITH MUTATED CD28 COSTIMULATORY DOMAINS | Final Rejection | H.Lee Moffitt Cancer Center and Research Institute, Inc. |
| 18186856 | MRNA THERAPEUTIC COMPOSITIONS AND USE TO TREAT DISEASES AND DISORDERS | Non-Final OA | Translate Bio, Inc. |
| 18837056 | TWO-DIMENSIONAL CULTURE METHOD HAVING CLEAR CHEMICAL COMPOSITION FOR CULTURING THREE-DIMENSIONAL INTESTINAL ORGANOID-DERIVED INTESTINAL STEM CELL AGGREGATE | Non-Final OA | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy